18 analyst firms have reported ratings in the last year. The last downgrade for Baxter International Inc happened on July 15, 2024 when Morgan Stanley changed their price target from $39 to $30 ...

This was the stock's second consecutive day of losses.

DEERFIELD, Ill., May 06, 2025--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of ...

Revenue: US$2.63b (down 27% from 1Q 2024). Net income: US$64.0m (up 73% from 1Q 2024). Profit margin: 2.4% (up from 1.0% in 1Q 2024). EPS: US$0.13 (up from US$0.073 in 1Q 2024). Trump has pledged ...

Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient ...

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend ...

Baxter International, a prominent healthcare and pharmaceutical manufacturer, reports that President Trump's tariffs will likely cost the company $60 million to $70 million this year. Baxter makes a ...

With a market cap of $15.6 billion, Baxter International Inc. (BAX) is a global healthcare company that specializes in medical products and therapies, with a strong focus on renal care ...

According to Benzinga Pro, Baxter Intl's peer group average for short interest as a percentage of float is 4.12%, which means ...

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies ...